MX341663B - Nanopolvo de compuesto organico, metodo para producirlo y su suspension. - Google Patents

Nanopolvo de compuesto organico, metodo para producirlo y su suspension.

Info

Publication number
MX341663B
MX341663B MX2014010772A MX2014010772A MX341663B MX 341663 B MX341663 B MX 341663B MX 2014010772 A MX2014010772 A MX 2014010772A MX 2014010772 A MX2014010772 A MX 2014010772A MX 341663 B MX341663 B MX 341663B
Authority
MX
Mexico
Prior art keywords
organic compound
less
suspension
nanopolvo
produce
Prior art date
Application number
MX2014010772A
Other languages
English (en)
Other versions
MX2014010772A (es
Inventor
Takahiro Tada
Kazuhiro Kagami
Shiro Yokota
Original Assignee
Activus Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Activus Pharma Co Ltd filed Critical Activus Pharma Co Ltd
Publication of MX2014010772A publication Critical patent/MX2014010772A/es
Publication of MX341663B publication Critical patent/MX341663B/es

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B02—CRUSHING, PULVERISING, OR DISINTEGRATING; PREPARATORY TREATMENT OF GRAIN FOR MILLING
    • B02C—CRUSHING, PULVERISING, OR DISINTEGRATING IN GENERAL; MILLING GRAIN
    • B02C17/00—Disintegrating by tumbling mills, i.e. mills having a container charged with the material to be disintegrated with or without special disintegrating members such as pebbles or balls
    • B02C17/18—Details
    • B02C17/20—Disintegrating members
    • B02C17/205—Adding disintegrating members to the tumbling mill
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B02—CRUSHING, PULVERISING, OR DISINTEGRATING; PREPARATORY TREATMENT OF GRAIN FOR MILLING
    • B02C—CRUSHING, PULVERISING, OR DISINTEGRATING IN GENERAL; MILLING GRAIN
    • B02C23/00—Auxiliary methods or auxiliary devices or accessories specially adapted for crushing or disintegrating not provided for in preceding groups or not specially adapted to apparatus covered by a single preceding group
    • B02C23/06—Selection or use of additives to aid disintegrating
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B02—CRUSHING, PULVERISING, OR DISINTEGRATING; PREPARATORY TREATMENT OF GRAIN FOR MILLING
    • B02C—CRUSHING, PULVERISING, OR DISINTEGRATING IN GENERAL; MILLING GRAIN
    • B02C23/00—Auxiliary methods or auxiliary devices or accessories specially adapted for crushing or disintegrating not provided for in preceding groups or not specially adapted to apparatus covered by a single preceding group
    • B02C23/18—Adding fluid, other than for crushing or disintegrating by fluid energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Food Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Dispersion Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Colloid Chemistry (AREA)
  • Physical Or Chemical Processes And Apparatus (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

OBJETIVO El objetivo de la presente invención proporcionar de manera conveniente un nanopolvo de compuesto orgánico, a bajo costo y con menos contaminación de impurezas a eliminar. MEDIOS PARA RESOLVER La presente invención se refiere a un nanopolvo de compuesto orgánico que comprende un compuesto orgánico granular con un diámetro de partícula promedio de 500 nm o menos y un diámetro-90% menor de 1500 nm y un compuesto de carbohidrato que comprende al menos un azúcar o un alcohol de azúcar y en una cantidad de 0.3 veces o más, en masa, con relación a la cantidad del compuesto orgánico, un método para producirlo y una suspensión que contiene el compuesto orgánico disperso en un medio de dispersión líquido en el que el compuesto orgánico es insoluble o poco soluble. Dibujos seleccionados: Ninguno.
MX2014010772A 2012-05-11 2013-05-11 Nanopolvo de compuesto organico, metodo para producirlo y su suspension. MX341663B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2012108972 2012-05-11
PCT/JP2013/003023 WO2013168437A1 (ja) 2012-05-11 2013-05-11 有機化合物ナノ粉体、その製造方法ならびに懸濁液

Publications (2)

Publication Number Publication Date
MX2014010772A MX2014010772A (es) 2014-10-14
MX341663B true MX341663B (es) 2016-08-30

Family

ID=49550500

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014010772A MX341663B (es) 2012-05-11 2013-05-11 Nanopolvo de compuesto organico, metodo para producirlo y su suspension.

Country Status (17)

Country Link
US (1) US9278071B2 (es)
EP (1) EP2848243B1 (es)
JP (1) JP6054380B2 (es)
KR (1) KR101772263B1 (es)
CN (1) CN104203217B (es)
AU (1) AU2013259150B2 (es)
BR (1) BR112014028431B1 (es)
CA (1) CA2867236C (es)
ES (1) ES2952419T3 (es)
IL (1) IL234327B (es)
IN (1) IN2014MN02002A (es)
MX (1) MX341663B (es)
PL (1) PL2848243T3 (es)
PT (1) PT2848243T (es)
RU (1) RU2613109C2 (es)
TW (1) TWI579004B (es)
WO (1) WO2013168437A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3067045T3 (pl) * 2013-11-08 2025-04-07 Activus Pharma Co., Ltd. Preparat wodnej zawiesiny zawierający nanocząstki makrolidowego środka przeciwbakteryjnego
AU2015212726B2 (en) * 2014-02-03 2018-02-01 Apurano Pharmaceuticals Gmbh Nanosuspension of natural materials and preparation method thereof
EP3118276A4 (en) * 2014-03-10 2017-10-25 The University of Tokyo Water-dispersible amorphous particles and method for preparing same
EP3470059B1 (en) * 2015-01-26 2020-04-01 Bausch & Lomb Incorporated Ophthalmic suspension composition
TWI773641B (zh) * 2015-05-08 2022-08-11 日商活效製藥股份有限公司 含有糖皮質類固醇（ｇｌｕｃｏｃｏｒｔｉｃｏｉｄｓ）之奈米微粒子之水性懸浮液劑
JP6612081B2 (ja) * 2015-07-31 2019-11-27 東洋精糖株式会社 α−グルコシルルチン含有プテリジン誘導体ナノ粒子の製造方法およびα−グルコシルルチン含有プテリジン誘導体ナノ粒子
RU2710952C2 (ru) * 2015-08-04 2020-01-14 Апурано Лайф Сайенсис Гмбх Наносуспензия, содержащая частицы и экстракт природных материалов
CZ307916B6 (cs) * 2017-05-08 2019-08-21 mcePharma s. r. o. Orodispergovatelná tableta s biodostupným kurkuminem a její použití
CN111253498B (zh) * 2020-03-10 2021-11-09 中国科学院海洋研究所 一种褐藻多糖衍生物纳米胶束的制备
PT3962455T (pt) 2020-05-18 2022-10-13 Orexo Ab Nova composição farmacêutica para entrega de fármacos
CN113209031A (zh) * 2021-04-30 2021-08-06 青岛农业大学 一种负载两性霉素B与β-1，3-葡聚糖酶的双靶向复合纳米体系及其制备方法、应用
CN113620937A (zh) * 2021-08-03 2021-11-09 湖南复瑞生物医药技术有限责任公司 一种高纯度小粒径普仑司特的制备方法
AR127780A1 (es) 2021-11-25 2024-02-28 Orexo Ab Nueva composición farmacéutica que comprende adrenalina
GB202117016D0 (en) 2021-11-25 2022-01-12 Orexo Ab New pharmaceutical device
CN116270477B (zh) * 2023-03-13 2025-05-30 华南理工大学 一种无定形态姜黄素纳米颗粒及其制备方法与应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
IL143197A0 (en) 1998-11-20 2002-04-21 Rtp Pharma Inc Dispersible phospholipid stabilized microparticles
JP4969761B2 (ja) * 2000-08-31 2012-07-04 オバン・エナジー・リミテッド 所望粒度を持つ固体基材の小粒子および第一材料の小粒状物を含む相乗作用性混合物を製造する方法
JP2006089386A (ja) 2004-09-21 2006-04-06 Nippon Tenganyaku Kenkyusho:Kk ステロイドまたはステロイド誘導体を含有する懸濁性医薬組成物
KR20090027734A (ko) * 2006-07-27 2009-03-17 (주)아모레퍼시픽 난용성 약물의 나노입자를 포함하는 분말의 제조방법
TWI405590B (zh) * 2007-04-06 2013-08-21 活效製藥股份有限公司 微粉碎化有機化合物粒子之製法
EP2345426B1 (en) 2008-09-19 2014-03-05 Activus Pharma Co., Ltd. Composite organic compound powder for medical use, method for producing same and suspension of same
US8828445B2 (en) * 2010-03-22 2014-09-09 Bio-Synectics Inc. Method for preparing nano-particles utilizing a saccharide anti-coagulant

Also Published As

Publication number Publication date
ES2952419T3 (es) 2023-10-31
WO2013168437A1 (ja) 2013-11-14
TWI579004B (zh) 2017-04-21
BR112014028431A2 (pt) 2017-06-27
KR101772263B1 (ko) 2017-08-28
EP2848243B1 (en) 2023-07-12
IL234327B (en) 2018-06-28
PL2848243T3 (pl) 2024-04-08
MX2014010772A (es) 2014-10-14
RU2014148792A (ru) 2016-06-27
CA2867236A1 (en) 2013-11-14
AU2013259150A1 (en) 2014-08-28
US20140328917A1 (en) 2014-11-06
BR112014028431B1 (pt) 2022-01-11
RU2613109C2 (ru) 2017-03-15
EP2848243A4 (en) 2015-12-23
US9278071B2 (en) 2016-03-08
CA2867236C (en) 2017-02-28
PT2848243T (pt) 2023-08-02
JPWO2013168437A1 (ja) 2016-01-07
IN2014MN02002A (es) 2015-08-07
CN104203217B (zh) 2017-02-15
KR20150008376A (ko) 2015-01-22
AU2013259150B2 (en) 2016-07-14
CN104203217A (zh) 2014-12-10
EP2848243A1 (en) 2015-03-18
TW201400142A (zh) 2014-01-01
JP6054380B2 (ja) 2016-12-27

Similar Documents

Publication Publication Date Title
MX341663B (es) Nanopolvo de compuesto organico, metodo para producirlo y su suspension.
Moezzi et al. Zinc oxide particles: Synthesis, properties and applications
CL2015000986A1 (es) Composiciones útiles en el tratamiento y control de enfermedades en plantas y métodos asociados.
WO2016025051A3 (en) Graphene quantum dot-polymer composites and methods of making the same
MX2016001023A (es) Formulaciones que contienen dapagliflozina amorfa.
WO2015034812A3 (en) A new ketogenic diet and its use in treating the critically ill
CO2017001998A2 (es) Proceso para incrementar la producción de biomasa y esporas de bacterias promotoras del crecimiento vegetal del género bacillus.
MX2017001815A (es) Celulas hospederas modificadas y oligosacaridos hibridos para su uso en produccion de bioconjugados.
MY166868A (en) Bactericidal agent composition
EA201690849A1 (ru) Составы со стриголактоном и их применения
BR112015000892A2 (pt) processo de preparar ácido acrílico
MX363137B (es) Metodos para incrementar el contenido de caucho extraible de material de planta no hevea.
EA201590161A1 (ru) Составы этанерцепта, отличающиеся заметным уменьшением содержания частиц довидимого диапазона
AR094422A1 (es) Concentración de suspensiones
UA113190C2 (xx) Презерватив з покриттям
BR112015009773A2 (pt) suspensões líquidas de polímeros
CR20120082A (es) Conservantes de derivados de quitina
UY34852A (es) Concentrados de suspensión herbicida de alta resistencia.
EP2962082A4 (en) Liquid to liquid biological particle concentrator with disposalbe fluid path
WO2014199322A3 (en) Wear resistant compositions with low particulate contamination and method of making those compositions
BR112012028368A2 (pt) suspensão e composição de torta contendo derivado carbo estirila e óleo de silicone e/ou derivado de óleo de silicone.
CL2015000226A1 (es) Proceso para la concentracion de una suspension acuosa de particulas solidas que comprende la adicion de al menos un floculante polimerico organico a la suspension acuosa y en donde se añade al menos un agente activo a los solidos en la corriente de reciclado.
PE20151085A1 (es) Composicion de xantofilas
WO2015082048A3 (en) Black polymer particles
IN2013MU01331A (es)

Legal Events

Date Code Title Description
FG Grant or registration